Suppr超能文献

布洛芬会干扰抗高血压药物的疗效。一项将布洛芬与对乙酰氨基酚进行比较的随机、双盲、安慰剂对照试验。

Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.

作者信息

Radack K L, Deck C C, Bloomfield S S

机构信息

Department of Internal Medicine, University Hospital, University of Cincinnati, Ohio.

出版信息

Ann Intern Med. 1987 Nov;107(5):628-35. doi: 10.7326/0003-4819-107-5-628.

Abstract

STUDY OBJECTIVE

To assess the effects of ibuprofen on blood pressure control in patients being treated with antihypertensive drugs.

DESIGN

Randomized, blinded, placebo-controlled, parallel trial of ibuprofen compared with acetaminophen and with placebo in 3-week treatment periods.

SETTING

A general internal medicine clinic at a university hospital.

PATIENTS

Forty-five patients with essential hypertension controlled by treatment with at least two antihypertensive drugs were enrolled. Of these, 41 completed the study; treatment was discontinued in 3 of the 15 patients in the ibuprofen group due to breakage of the drug capsules, and after randomization in 1 of the 14 patients in the placebo group due to unstable angina. All 15 patients in the acetaminophen group completed the study.

INTERVENTIONS

All previous antihypertensive regimens were continued. During the 3-week treatment, ibuprofen, 400 mg, was administered orally every 8 hours; acetaminophen, 1 g, orally every 8 hours; or placebo, 2 capsules, orally every 8 hours.

MEASUREMENTS AND MAIN RESULTS

In the ibuprofen group, the mean increase from baseline after 3 weeks of treatment was significant in the average supine diastolic blood pressure (6.4 mm Hg; 95% confidence interval [CI], 1.05 to 11.75; p = 0.0239); supine mean arterial pressure (6.6 mm Hg; 95% CI, 1.25 to 11.95; p = 0.0205); and sitting mean arterial pressure (5.8 mm Hg; 95% CI, 1.57 to 10.04; p = 0.0123). The mean increase in blood pressure variables in the ibuprofen group was significantly different compared with the mean increase in the variables in the placebo group after 3 weeks of treatment: supine systolic blood pressure (7.1 mm Hg compared with -4.5 mm Hg; 95% CI for the difference in means, 2.5 to 20.6; p = 0.0133); supine diastolic pressure (6.4 mm Hg compared with 0.0; 95% CI for difference in means, 0.87 to 12.4; p = 0.0250); supine mean arterial pressure (6.6 mm Hg compared with -1.5; 95% CI for difference in means, 2.0 to 14.2; p = 0.0110); sitting systolic pressure (6.8 mm Hg compared with -3.7; 95% CI for difference in means, 2.0 to 19.0; p = 0.0169); sitting diastolic pressure (5.3 mm Hg compared with -1.1; 95% CI for difference in means, 0.76 to 12.1; p = 0.0273); and sitting mean arterial pressure (5.8 mm Hg compared with -2.0; 95% CI for difference in means, 1.5 to 14.1; p = 0.0169).(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

研究目的

评估布洛芬对正在接受抗高血压药物治疗患者血压控制的影响。

设计

在3周治疗期内,将布洛芬与对乙酰氨基酚及安慰剂进行随机、双盲、安慰剂对照、平行试验。

地点

一所大学医院的普通内科门诊。

患者

纳入45例经至少两种抗高血压药物治疗血压得到控制的原发性高血压患者。其中,41例完成研究;布洛芬组15例患者中有3例因药物胶囊破裂而中断治疗,安慰剂组14例患者中有1例在随机分组后因不稳定型心绞痛中断治疗。对乙酰氨基酚组的15例患者均完成研究。

干预措施

继续之前所有的抗高血压治疗方案。在3周治疗期间,每8小时口服一次400毫克布洛芬;每8小时口服一次1克对乙酰氨基酚;或每8小时口服2粒安慰剂胶囊。

测量指标及主要结果

在布洛芬组,治疗3周后平均仰卧舒张压较基线的平均升高幅度显著(6.4毫米汞柱;95%置信区间[CI],1.05至11.75;p = 0.0239);仰卧平均动脉压(6.6毫米汞柱;95% CI,1.25至11.95;p = 0.0205);坐位平均动脉压(5.8毫米汞柱;95% CI,1.57至10.04;p = 0.0123)。治疗3周后,布洛芬组血压变量的平均升高幅度与安慰剂组变量的平均升高幅度相比有显著差异:仰卧收缩压(7.1毫米汞柱对比 -4.5毫米汞柱;均值差异的95% CI,2.5至20.6;p = 0.0133);仰卧舒张压(6.4毫米汞柱对比0.0;均值差异的95% CI,0.87至12.4;p = 0.0250);仰卧平均动脉压(6.6毫米汞柱对比 -1.5;均值差异的95% CI,2.0至14.2;p = 0.0110);坐位收缩压(6.8毫米汞柱对比 -3.7;均值差异的95% CI,2.0至19.0;p = 0.0169);坐位舒张压(5.3毫米汞柱对比 -1.1;均值差异的95% CI,0.76至12.1;p = 0.0273);坐位平均动脉压(5.8毫米汞柱对比 -2.0;均值差异的95% CI,1.5至14.1;p = 0.0169)。(摘要截断于400字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验